Comparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer
British Journal of Cancer
Aminolevulinic acid (ALA)-based photodynamic therapy (PDT) provides selective uptake and conversion of ALA into protoporphyrin IX (PpIX) in actinic keratosis and squamous cell carcinoma, yet large response variations in effect are common between individuals. The aim of this study was to compare pre-treatment strategies that increase the therapeutic effect, including fractionated light delivery during PDT (fPDT) and use of iron chelator desferrioxamine (DFO), separately and combined.
Ribeiro de Souza, Ana Luiza; Marra, Kayla; Gunn, Jason; Samkoe, Kimberly; Kanick, Stephen; Davis, Scott; Chapman, M Shane; Maytin, Edward; Hasan, Tayyaba; and Pogue, Brian, "Comparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer" (2016). Open Dartmouth: Faculty Open Access Articles. 73.